Abstract
It is generally accepted that many factors, such as hypertension, vascular disease, renal calculi and infection, may contribute to renal disease in patients with gout. However, these are usually regarded as secondary phenomena which are often superimposed on a primary nephropathy. Most studies of the gouty kidney, however, have found evidence of a primary nephropathy with deposits of urate and uric acid crystals (1, 2, 3); Talbott and Terplan (4), in a study of almost two hundred kidneys, concluded that “the only distinct pathological feature of the gouty kidney is the presence of urate crystals”. Crystallographic studies indicated that these crystals were either acicular crystals of monosodium urate monohydrate (urate or MSUM) or deposits of uric acid (UA) (5). Subsequent studies of urinary urate over-excretion, either following chemotherapy of malignancy (6) or due to HPRT deficiency (7, 8), have established the importance of intratubular uric acid deposition in the development of an acute uric acid nephropathy. Interstitial micro-tophi containing urate crystals have also been demonstrated in gouty kidneys and there is suggestive evidence that these might develop not only due to local formation, but also by the passage of uric acid crystals through the lining epithelium of the distal nephron into the interstitial tissues. This has been demonstrated with other crystals in animals (9). Indeed, urate crystals have been demonstrated by electron microscopy within the tubular lining cells of patients with leukemia (10). Thus, there is support for the hypothesis that, at least in some cases, renal damage from uric acid begins by a reaction between intraluminal uric acid crystals and tubular lining cells of the distal nephron. For this reason, a study was planned of the reaction between cultured renal tubular cells and crystals of urate and uric acid.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J.B. Brown and G.K. Mallory, Renal changes in gout, N Engl J Med 243: 325–329 (1950).
R. Bluestone, J. Waisman and J.R. Klinenberg, The gouty kidney, Seminars in Arthritis and Rheumatism 7: 97–113 (1977).
B.T. Emmerson, Gout, uric acid and renal disease, Med J Aust 1: 403–405 (1976).
J.H. Talbot and K.L. Terplan, The kidney in gout, Medicine (Baltimore) 39: 405–462 (1960).
J.E. Seegmiller and P.D. Frazier, Biochemical considerations of the renal damage of gout, Ann Rheum Dis 25: 668–672 (1966).
K.G. Barry, R.H. Hunter, T.E. Davis and W.H. Crosby, AMA Archives Int Med 111: 453–459 (1963).
B.T. Emmerson and P.G. Row, An evaluation of the pathogenesis of the gouty kidney, Kidney Int 8: 65–71 (1975).
J.A. Batch, R.P. Riek, R.B. Gordon, J.R. Burke and B.T. Emmerson, Renal failure in infancy due to urate over-production, Aust NZ J Med 14: 852–854 (1984).
D.A. Farebrother, P. Hatfield, et al, Experimental crystal nephropathy (one year study in the pig), Clinical Nephrology 4: 243 (1975).
Y.S. Kanwar and J.R. Manaligod, Leukemic urate nephropathy, Arch Pathol 99: 467–72 (1975).
M.J. Rindler, L.M. Chuman, L. Shaffer and M.H. Saier Jr, Retention of differentiated properties in an established dog kidney epithelial cell line (MDCK), J Cell Biol 81: 635–648 (1979).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Plenum Press, New York
About this chapter
Cite this chapter
Emmerson, B.T., Axelsen, R., Cross, M. (1989). A Model of Gout Nephropathy. In: Mikanagi, K., Nishioka, K., Kelley, W.N. (eds) Purine and Pyrimidine Metabolism in Man VI. Advances in Experimental Medicine and Biology, vol 253A. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5673-8_33
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5673-8_33
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5675-2
Online ISBN: 978-1-4684-5673-8
eBook Packages: Springer Book Archive